GlobeNewsWire
08 Dec 2025, 15:30 UTC · 49w ago
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Impact · against what's priced in
The data for KOMZIFTI in combination therapy represents a material expansion of the addressable market for Kura Oncology and Kyowa Kirin, moving the drug from a relapsed/refractory salvage therapy toward first-line treatment. High remission rates (86% CRc in newly diagnosed NPM1-m AML) and a lack of additive toxicity provide strong fundamental support for the ongoing registrational trials.
- KURA+0.70
No priced-in read yet





